Methylphenidate and Atomoxetine Enhance Prefrontal Function Through α2-Adrenergic and Dopamine D1 Receptors
Gamo NJ, Wang M, Arnsten AF. Methylphenidate and Atomoxetine Enhance Prefrontal Function Through α2-Adrenergic and Dopamine D1 Receptors. Journal Of The American Academy Of Child & Adolescent Psychiatry 2010, 49: 1011-1023. PMID: 20855046, PMCID: PMC2999884, DOI: 10.1016/j.jaac.2010.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAnimalsAppetitive BehaviorAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityBrain MappingCentral Nervous System StimulantsChildDisease Models, AnimalDose-Response Relationship, DrugFemaleHumansMacaca mulattaMaleMemory, Short-TermMethylphenidateNerve NetOrientationPrefrontal CortexPropylaminesPyramidal CellsReceptors, Adrenergic, alpha-2Receptors, Dopamine D1SaccadesConceptsAttention-deficit/hyperactivity disorder treatmentOptimal dosesPFC cognitive functionDopamine receptor antagonistDopamine D1 receptorsAttention-deficit/hyperactivity disorderAdrenoceptor antagonistPrefrontal cortex functionΑ2-adrenergicCellular levelReceptor antagonistD1 receptorsDopamine receptorsTherapeutic effectReceptor mechanismsSCH23390Moderate dosesAtomoxetineIndirect stimulationDisorder treatmentHigh dosesCortex functionPersistent firingCognitive functionReceptor action